ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00483301
Recruitment Status : Completed
First Posted : June 7, 2007
Last Update Posted : May 3, 2012
Sponsor:
Collaborators:
Celgene Corporation
Bayer
Information provided by (Responsible Party):
Jose Lutzky, Mt. Sinai Medical Center, Miami

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : August 2009
  Actual Study Completion Date : August 2009

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 May 20, 2014
June 19, 2014